BENEFIT (7-year follow-up) (2016) — Trial Summary
BENEFIT (7-year follow-up) (2016): Final 7-year (84-month) results of the phase 3 BENEFIT trial comparing more- and less-intensive belatacept regimens with cyclosporine in kidney-transplant recipients (n=666).
References
- Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016;374(4):333-343.